Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Small RNA Drugs: Therapeutic Strategies, Sequence Analysis, and Chemical Modifications
Bio Sequence
7 min read
Small RNA Drugs: Therapeutic Strategies, Sequence Analysis, and Chemical Modifications
24 September 2024
siRNA and ASO are two nucleic acid-based gene silencing technologies that achieve precise regulation of gene expression by complementary pairing with specific mRNA sequences.
Read →
Promising Phase 1 Results for Trishula Therapeutics' TTX-030 in Metastatic Pancreatic Cancer
Latest Hotspot
4 min read
Promising Phase 1 Results for Trishula Therapeutics' TTX-030 in Metastatic Pancreatic Cancer
24 September 2024
Trishula Therapeutics' Phase 1 trial of TTX-030 shows encouraging results for first-line treatment of metastatic pancreatic cancer.
Read →
Zealand: Latest Developments in the Insulin Analog Petrelintide for Weight Management
Hot Spotlight
3 min read
Zealand: Latest Developments in the Insulin Analog Petrelintide for Weight Management
24 September 2024
the Danish pharmaceutical company Zealand Pharma announced clinical Phase 1 data for its long-acting amylin analogue, Petrelintide, which is being studied for weight management.
Read →
Beacon Therapeutics Releases 36-Month Data on AGTC-501 from HORIZON Phase I/2 Trial for XLRP
Latest Hotspot
3 min read
Beacon Therapeutics Releases 36-Month Data on AGTC-501 from HORIZON Phase I/2 Trial for XLRP
24 September 2024
Beacon Therapeutics Shares 36-Month Interim Data from HORIZON Phase I/2 Trial of AGTC-501 for XLRP Patients.
Read →
Novo Nordisk: A long-acting, selective human insulin analog, NN1213, for weight management
Hot Spotlight
4 min read
Novo Nordisk: A long-acting, selective human insulin analog, NN1213, for weight management
24 September 2024
Amylin is a pancreatic peptide consisting of 37 amino acids that is co-stored and co-secreted with insulin in response to nutrient intake.
Read →
RYBREVANT® Approved in U.S. as Exclusive Second-Line Targeted Treatment for EGFR-Mutated Advanced Lung Cancer
Latest Hotspot
4 min read
RYBREVANT® Approved in U.S. as Exclusive Second-Line Targeted Treatment for EGFR-Mutated Advanced Lung Cancer
24 September 2024
RYBREVANT® (amivantamab-vmjw) with standard care now approved in the U.S. as the sole targeted treatment reducing disease progression risk by over 50% for second-line EGFR-mutated advanced lung cancer.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 24
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 24
24 September 2024
Sep 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Edgewise Therapeutics Announces Positive Phase 1 and Phase 2 CIRRUS-HCM Study Results in Obstructive Hypertrophic Cardiomyopathy
Latest Hotspot
4 min read
Edgewise Therapeutics Announces Positive Phase 1 and Phase 2 CIRRUS-HCM Study Results in Obstructive Hypertrophic Cardiomyopathy
24 September 2024
Edgewise Therapeutics Reports Favorable Results from Phase 1 Study in Healthy Volunteers and Phase 2 CIRRUS-HCM Study in Obstructive Hypertrophic Cardiomyopathy Patients.
Read →
4DMT Highlights Promising Clinical Results for 4D-150 and Reveals Phase 3 Strategy at Wet AMD Program Event
Latest Hotspot
4 min read
4DMT Highlights Promising Clinical Results for 4D-150 and Reveals Phase 3 Strategy at Wet AMD Program Event
24 September 2024
4DMT Showcases Strong and Lasting Clinical Outcomes for 4D-150 and Unveils 4FRONT Phase 3 Program Plan at 4D-150 Wet AMD Development Event.
Read →
Promising Outcomes from Transcenta's Osemitamab Triple Trial in G/GEJ Cancer at ESMO 2024
Latest Hotspot
4 min read
Promising Outcomes from Transcenta's Osemitamab Triple Trial in G/GEJ Cancer at ESMO 2024
24 September 2024
Transcenta Shares Promising Results from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024.
Read →
Phase III trial results indicate Xofluza greatly lowers the spread of flu viruses
Latest Hotspot
3 min read
Phase III trial results indicate Xofluza greatly lowers the spread of flu viruses
24 September 2024
Genentech revealed favorable topline results from the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).
Read →
Global New Drug Research and Development Progress Weekly Report (9.16-9.22)
Global New Drug Research and Development Progress Weekly Report (9.16-9.22)
23 September 2024
Summary of Key R&D Progress in Global Innovative Drugs from September 16 to September 22.
Read →